Segmentation - Schedule of Net Loss and Adjusted EBITDA (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Segment Reporting [Line Items] | ||||
| Net loss (GAAP) | $ (115,227,348) | $ (2,902,313) | $ (118,786,726) | $ (7,725,194) |
| Adjustments | ||||
| Depreciation and amortization expenses | 335,966 | 180,787 | 646,233 | 349,836 |
| Adjustments Share based compensation within | ||||
| Research and development | 2,614,022 | 1,206,612 | 4,742,435 | 4,527,603 |
| Selling and marketing | 375,989 | 248,716 | 834,952 | 576,665 |
| General and administrative | 3,849,526 | 1,146,373 | 7,451,257 | 2,047,525 |
| Change in fair value of derivative liabilities | (108,294,223) | (105,317,692) | ||
| Single Reportable Segment [Member] | ||||
| Segment Reporting [Line Items] | ||||
| Net loss (GAAP) | (115,227,348) | (2,902,313) | (118,786,726) | (7,725,194) |
| Adjustments | ||||
| Net interest (income) expense | (477,253) | (12,805) | (512,778) | (42,915) |
| Depreciation and amortization expenses | 335,966 | 180,787 | 646,233 | 349,836 |
| EBITDA | (115,368,635) | (2,734,330) | (118,653,271) | (7,418,272) |
| Adjustments Share based compensation within | ||||
| Research and development | 436,808 | 261,285 | 676,982 | 2,778,608 |
| Selling and marketing | 46,320 | 65,299 | 92,386 | 170,448 |
| General and administrative | 509,959 | 130,294 | 839,994 | 437,675 |
| Change in fair value of derivative liabilities | 108,294,223 | 105,317,692 | ||
| Business combination and post-closing expenses | 622,980 | 214,101 | 2,164,930 | 214,101 |
| Adjusted EBITDA | $ (5,458,343) | $ (2,063,351) | $ (9,561,286) | $ (3,817,439) |
| X | ||||||||||
- Definition Amount of adjusted EBITDA. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of business combination and post-closing expenses. No definition available.
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of interest income (expense) classified as operating. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Details
|